University of California (UC)-San Francisco researchers, in collaboration with the Brazilian Biobank for Aging Studies (BBAS) at the University of São Paulo, have shown that the earliest stages of the brain degeneration associated with Alzheimer’s disease (AD) are linked to neuropsychiatric symptoms including anxiety, depression, loss of appetite, and sleep disturbances.
The findings—published in their final version October 15, 2018 in the print edition of the Journal of Alzheimer’s Disease following preliminary online publication in September—could lead to earlier diagnosis of AD and prove a valuable biomarker in the development of therapies to slow the course of the disease, the authors say, but may also have broader implications for understanding the biological basis of psychiatric symptoms in older adults.
Though commonly associated with memory loss and dementia, Alzheimer’s disease is actually a progressive neurodegenerative condition that can be detected in a brain autopsy decades before these classic cognitive symptoms occur. A “Holy Grail” of Alzheimer’s research is to develop treatments that could be given in the disease’s earliest stages to protect brain tissue from further loss and to slow or prevent the eventual development of dementia. However, the development of such drugs will require a better understanding of the biology that drives the first stages of the disease and the ability to diagnose patients early enough to prevent extensive loss of neural tissue.
Many studies have identified correlations between neuropsychiatric symptoms such as depression, anxiety, and sleep disturbances and an eventual Alzheimer’s diagnosis, and some have even proposed that these symptoms could be used as biomarkers for the disease in its earliest stages. But the relationship between the two has remained murky. In fact, some researchers have proposed that depression and other psychiatric conditions, or even the drugs used to treat these conditions, could themselves be triggers that lead to the onset of dementia decades later, much like occasional seizures can contribute to the development of chronic epilepsy.
Now members of the lab of Lea Grinberg, MD, PhD, in the UCSF Weill Institute for Neurosciences’ Memory and Aging Center, working with their Brazilian colleagues, have shown that psychiatric symptoms are tightly linked to the earliest stages of Alzheimer’s brain pathology. These results strongly suggest that neuropsychiatric conditions or treatments do not cause Alzheimer’s, but could be the earliest warning signs of the disease.
“The discovery that the biological basis for these symptoms is the early Alzheimer’s pathology itself was quite surprising,” Grinberg says in a release. “It suggests these people with neuropsychiatric symptoms are not at risk of developing Alzheimer’s disease— they already have it.”
The research took advantage of São Paulo’s unique century-old autopsy service, which is mandated in all deaths and conducts approximately 15,000 autopsies per year. In 2003, as part of her doctoral research, Grinberg co-founded the BBAS to collect brain tissue samples from these autopsies, and BBAS has since grown to become the largest such resource in the world.
Most postmortem brain studies of AD use relatively small “convenience samples” from older individuals who already show signs of memory loss or dementia. Because multiple brain pathologies can accumulate with age, it can be difficult to tightly link specific AD-related symptoms to brain abnormalities detected in these samples. Thanks to the BBAS collaboration, however, Grinberg’s team was able to avoid these potential pitfalls by drawing from a much larger population, selecting brains from younger and healthier individuals, and excluding tissue samples with multiple competing pathologies.
In the new study, lead author Alex Ehrenberg, a neuropathology research associate in the Grinberg lab, worked closely with Claudia Suemoto MD, PhD, and other colleagues from the University of São Paulo to study the brains of 1,092 seemingly healthy adults over the age of 50 who closely represented the general population of São Paulo. The researchers excluded 637 brains that showed neurological signs of brain abnormalities not related to AD, leaving 455 brains with either no signs of degeneration or a range of AD-related pathology.
AD pathology is characterized by buildup of telltale neurofibrillary (NF) tangles and amyloid-beta (A?) plaques, paralleled by the atrophy of brain tissue in associated regions. The disease nearly always progresses in the same fashion, with NF tangles first appearing in brainstem regions associated with sleep, appetite, and emotional processing, while A? plaques first appear in cortical regions and then spread to deeper parts of the brain.
Ehrenberg and colleagues classified each of the 455 brains using standard scales of AD progression based on NF tangle and A? plaque accumulation. They then used statistical algorithms to test for a relationship between AD stage and reported changes in the brain donor’s cognitive and emotional status prior to their death, based on interviews with informants—typically relatives and caretakers—who had been in at least weekly contact with the deceased in the six months before their deaths, a gold-standard approach for neuropathological studies of degenerative brain diseases such as AD.
Ehrenberg’s computational analysis of the results found that in individuals whose brainstems showed the very earliest stages of NF tangles but lacked memory changes, family members and caretakers reported increased rates of one or more neuropsychiatric symptoms including agitation, anxiety, appetite changes, depression, and sleep disturbances, but lacked any noticeable memory problems. The next stage of the disease, as NF buildup increased in the brainstem and began to spread to other brain regions, was associated with increased odds of agitation, while only in later stages, as NF buildup began to reach the brain’s outer cortex, did the individuals begin showing signs of the dementia-like delusions and the cognitive and memory decline typically associated with AD.
Tellingly, the researchers found no link between buildup of A? plaques and these neuropsychiatric symptoms. Alzheimer’s researchers have long debated whether A? plaques or NF tangles—made up of clumps of a protein called “tau”—play an earlier or more central role in driving neurodegeneration in AD, and the authors believe the new findings add additional support for focusing on developing tau-targeted treatments, particularly given disappointing results from many recent trials of A?-targeted AD therapies.
“These results could have major implications for Alzheimer’s drug trials focused on early degenerative changes, where people have been seeking tractable clinical outcomes to target in addition to early cognitive decline,” Ehrenberg says. He adds that the findings will also be valuable as new technologies become available for detecting early stages of AD pathology in living patients, such as blood biopsies or PET brain imaging of tau, to aid the implementation of such novel biomarkers into clinical practice.
To Grinberg, the discovery that psychiatric symptoms such as depression or sleep disturbance in older adults may be linked to a specific biological phenomenon—namely accumulation of tau protein into NF tangles in the brainstem—is as exciting as the implications for Alzheimer’s disease itself.
“Because we generally don’t know the biological basis for most psychiatric conditions, we can’t do what we do for other diseases like diabetes or cancer; we can’t say, ‘You are having depression or sleep problems because of this disease in your brain, so let’s see if we can treat that disease,'” Grinberg says. “If we could use this new knowledge to find a way to reduce the burden of these conditions in aging adults, it would be absolutely huge.”
Image: Neuron damaged by Alzheimers disease. Credit: Grinberg Lab / UCSF